Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2021, Vol. 48 Issue (2): 448-452    DOI: 10.31083/j.ceog.2021.02.2219
Case Report Previous articles |
Uterine cervical carcinosarcoma; very rare and aggressive behavior; literature review
Özer Birge1, *(), Mehmet Sait Bakır1, Ceyda Karadag1, Can Dinc1, Tayup Simsek1
1Akdeniz University, Department of Gynecology Obstetrics, Division of Gynecologic Oncology, 07010 Antalya, Turkey
Download:  PDF(1972KB)  ( 101 ) Full text   ( 14 )
Export:  BibTeX | EndNote (RIS)      
Background: Carcinosarcoma is a rare malignancy of the female reproductive system, consisting of carcinomatous and sarcomatous components. It originates from the paramesonephric and mesonephric duct residues and is also called malignant mixed Mullerian tumor. Case Presentation: A 58-year-old post-menopausal woman, gravida 2, parity 2, who had no known diseases and no previous surgery presented to another clinic with pelvic pain that had been persisting for about a year and vaginal bleeding for the past month. There was continuous bleeding that was not associated with coitus, and cervical biopsy was reported as carcinosarcoma of heterologous type (the epithelial part was serous carcinoma and the mesenchymal part was chondrosarcoma); the patient was referred to our clinic and underwent evaluation. Conclusion: Effective follow-up is very important considering the aggressive clinical picture of carcinosarcoma cases. It should be kept in mind that metastasis may occur, especially in cases with hypercalcemia and deterioration of the general condition.
Key words:  Carcinosarcoma      Uterine cervix      Paramesonephric      Mesonephric      Hypercalcemia     
Submitted:  12 July 2020      Revised:  29 September 2020      Accepted:  15 October 2020      Published:  15 April 2021     
*Corresponding Author(s):  Özer Birge     E-mail:

Cite this article: 

Özer Birge, Mehmet Sait Bakır, Ceyda Karadag, Can Dinc, Tayup Simsek. Uterine cervical carcinosarcoma; very rare and aggressive behavior; literature review. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 448-452.

URL:     OR

[1] Z. Liu, M. Wan, H. Zhu. Fallopian tube ectopic pregnancy with renal duct cyst[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 986-987.
[2] P. Arsenijevic, A. Zivanovic, Z. Protrka, A. Dimitrijevic, M. Sorak, T. Vulovic, G. Vukcevic Globarevic, Z. Vilendecic, B. Andric, S. Arsenijevic. Cervical breaking point; a phenomenon unveiled during continuous controllable balloon dilatation[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 833-836.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] Sandeep K. Krishnan, Norman E. Lepor. Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management[J]. Reviews in Cardiovascular Medicine, 2016, 17(S1): 9 -21 .
[3] Ibrahim Sidiqi, Patrick Alexander. Current Advances in Endovascular Therapy for Infrapopliteal Artery Disease[J]. Reviews in Cardiovascular Medicine, 2015, 16(1): 36 -50 .
[4] Peter Shalit. Management of Dyslipidemia in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 38 -46 .
[5] Sophie Mavrogeni, Fabrizio Cantini, Gerald M. Pohost. Systemic Vasculitis: An Underestimated Cause of Heart Failure—Assessment by Cardiovascular Magnetic Resonance[J]. Reviews in Cardiovascular Medicine, 2013, 14(1): 49 -55 .
[6] George L. Smith. Appropriate Use Criteria: The Gold Standard, or a Mechanism for the Derogation of Clinical Judgment?[J]. Reviews in Cardiovascular Medicine, 2011, 12(2): 105 .
[7] Jeffrey W. Moses, Stephane Carlier, Issam Moussa. Lesion Preparation Prior to Stenting[J]. Reviews in Cardiovascular Medicine, 2004, 5(S2): 16 -21 .
[8] Steven V. Edelman. The Role of the Thiazolidinediones in the Practical Management of Patients With Type 2 Diabetes and Cardiovascular Risk Factors[J]. Reviews in Cardiovascular Medicine, 2003, 4(S6): 29 -37 .
[9] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[10] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .